Volume 22, Issue 2 (6-2019)                   J Arak Uni Med Sci 2019, 22(2): 67-74 | Back to browse issues page

XML Persian Abstract Print

1- Department of Endocrinology, Arak University of Medical Sciences, Arak, Iran. , afsanehtalaeii@yahoo.com
2- Department of Nephrology, Bushehr University of Medical Sciences, Bushehr, Iran.
3- Department of Statistic, Arak University of Medical Sciences, Arak, Iran.
Abstract:   (18047 Views)
Background and Aim: Regarding the controversy about the effects of atorvastatin on blood glucose control and diabetes, we evaluated the effects of atorvastatin on blood glucose and insulin resistance in the present study.
Materials and Methods: 88 type two diabetic patients (T2DP), were treated with anti-diabetes oral agents were enrolled in a double blind randomized clinical trial, placebo control. Then they were randomly classified into two 44 cases groups.  The intervention group took atorvastatin 40 mg daily and control group took placebo for three months and fasting blood glucose (FBS), insulin resistance, HbA1c and lipid profile were measured and compared at the beginning and the end of the study. Data were analyzed using student t-test and paired t-test.
Ethical Considerations: This study with research ethics code IR.ARAKMU.REC.90.108.10 has been approved by research ethics committee at Arak University of Medical Sciences.
Findings: After three months, insulin, insulin resistance and HbA1c decreased significantly in the intervention group than control group, while FBS non-significantly decreased. Total cholesterol and LDL cholesterol (Low density Lipoprotein) were also decreased.
Conclusion: It seems atorvastatin is effective to decrease FBS and insulin resistance in diabetic patients.
Full-Text [PDF 508 kb]   (970 Downloads)    
Type of Study: Original Atricle | Subject: Internal
Received: 2018/07/6 | Accepted: 2018/09/12

1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129:S1–45. [PubMed]
2. Shyu KG, Chua SK, Wang BW, Kuan P. Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages. J Biomed Sci. 2009; 27(16):50.
3. van Hoek M, van Tol A, van Vark-van der Zee LC, Jansen H, Kastelein JJ, Sijbrands EJ, et al. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. Curr Med Res Opin. 2009; 25(1):93-101.
4. White MF. The insulin signalling system and the IRS proteins. Diabetologia. 1997; 40(Suppl. 2):S2-S17.
5. Saltiel AR, Pessin JE. Insulin signaling pathways in time and space. Trends Cell Biol. 2002; 12:65-71.
6. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996; 271:665-668.
7. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307). J Biol Chem. 2000; 275:9047-9054.
8. Tello A, Marín F, Roldán V, García-Herola A, Lorenzo S, Climent VE, et al. Effect of maximum dose of atorvastatin on inflammation, thrombogenesis and fibrinolysis in high-risk patients with ischemic heart disease. Rev Esp Cardiol. 2005; 58(8):934-40.
9. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375 (9716):735–42.
10. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556–64.
11. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015; 58:1109–1117. doi: 10.1007/s00125-015-3528-5. [PubMed] [Cross Ref].
12. Erqou S, Lee CC, Adler AI. Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis. Diabetologia. 2014; 57:2444–2452. doi: 10.1007/s00125-014-3374-x. [PubMed] [Cross Ref].
13. Karampour-Qibchag Z, Heidari R. The effect of combined Atorvastatin and zinc sulfate on serum level of insulin, glucose, and histology of pancreas in streptozotocin-induced diabetic rats. Journal of Shahid Sadoughi University of Medical Sciences. 2018; 25 (11):864-877.
14. Zhang N, Huan Y, Huang H, Song GM, Sun SJ, Shen ZF. Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate. Acta Pharmacol Sin. 2010 ; 31(1): 35-42.
15. Simsek S, Schalkwijk CG, Wolffenbuttel BH.Effects of rosuvastatin and atorvastatin on glycaemiccontrol in Type 2 diabetes---the CORALLstudy.Diabet Med. 2012; 29(5): 628-31.
16. Strom A, Kolb H, Martin S, Herder C, Simon MC, Koenig W, et al. Improved preservation of residual beta cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One. 2012; 7(3):e33108.
17. Neerati P, Gade J. Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats. Eur J Pharm Sci. 2011; 42(3):285-9.
18. Ahmed D, Sharma M, Pillai KK. The effects of triple vs. dual and monotherapy with rosiglitazone, glimepiride, and atorvastatin on lipid profile and glycemic control in type 2 diabetes mellitus rats. Fundam Clin Pharmacol. 2012; 26(5):621-31.
19. Parida S, Swain TR, Routray SN, Maiti R. Effect of Atorvastatin on Glycaemic Parameters in Normoglycaemic and Prediabetic Subjects: A Prospective, Panel Study. J Clin Diagn Res. 2017; 11(2): FC04–FC09.doi: 10.7860/JCDR/2017/23741.9427.

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.